VEGFR
Os inibidores do Receptor do Fator de Crescimento Endotelial Vascular (VEGFR) são compostos que bloqueiam a sinalização do VEGFR, um receptor chave na via VEGF, crucial para a angiogênese. Os inibidores de VEGFR impedem a formação de novos vasos sanguíneos que fornecem nutrientes e oxigênio aos tumores, inibindo assim o crescimento tumoral. Esses inibidores são amplamente utilizados na terapia contra o câncer e na pesquisa para estudar os mecanismos da angiogênese e desenvolver tratamentos anticâncer. Na CymitQuimica, oferecemos uma ampla gama de inibidores de VEGFR de alta qualidade para apoiar sua pesquisa em oncologia, biologia vascular e angiogênese.
Foram encontrados 239 produtos de "VEGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidRef: TM-L1600
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarAngiogenesis related Compound Library
A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and highCor e Forma:Odour SolidRef: TM-L4800
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarVEGFR-2-IN-35
VEGFR-2-IN-35 (compound 7) is a potent inhibitor of VEGFR-2, exhibiting an IC50 of 37 nM.Fórmula:C25H19N3O3Pureza:98%Cor e Forma:SolidPeso molecular:409.44Conbercept
CAS:Conbercept (KH902) is a fusion protein comprising the second immunoglobulin C-like domain of FLT1 and the third and fourth immunoglobulin C-like domains of KDRPureza:98%Cor e Forma:LiquidTyrosine Kinase Inhibitor Library
A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase relatedCor e Forma:Odour SolidRef: TM-L2200
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarVEGFR-2-IN-33
VEGFR-2-IN-33 (Compound 4d), a potent VEGFR inhibitor with an IC50 value of 61.04 nM, demonstrates significant inhibition of HepG2 cell proliferation, achievingFórmula:C20H14N6O2S2Pureza:98%Cor e Forma:SolidPeso molecular:434.49FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Cor e Forma:LiquidVEGFR-2-IN-59
VEGFR-2-IN-59 (Compound 3h) is an inhibitor of VEGFR2 with an IC50 of 3.73 µM. It exhibits cytotoxicity in cancer cell lines A549, HT-29, A375, MCF7, and NHDF, with IC50 values of 20.91, 19.70, 9.63, 17.43, and 20.71 μM, respectively. VEGFR-2-IN-59 also inhibits tubular structure formation and demonstrates anti-angiogenic properties.Fórmula:C19H20N6O4Cor e Forma:SolidPeso molecular:396.45Z-7-Oxozeaenol
CAS:5Z-7-Oxozeaenol: TGF-β-activated kinase 1 inhibitor, IC50 8.1 nM; VEGF-R2 inhibitor, IC50 52 nM; weak MEK1 inhibitor, IC50 411 nM.Fórmula:C19H22O7Pureza:99%Cor e Forma:SolidPeso molecular:362.37VEGFR-2-IN-31
VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase andFórmula:C15H10F2N4OPureza:98%Cor e Forma:SolidPeso molecular:300.26T-1-MCPAB
T-1-MCPAB, a VEGFR-2 inhibitor with an IC50 of 0.135 µM, effectively suppresses MCF7 cell migration and has applications in cancer research [1].Pureza:98%Cor e Forma:Odour SolidVEGF-IN-1
VEGF-IN-1 (compound 6) reduces the release of VEGF in U87-MG cells and inhibits angiogenesis in vitro. Additionally, it suppresses cell proliferation by inducing autophagy in tumor cells, with an IC50 value of 28.35 μM against U87-MG cells.Fórmula:C27H22Cl2N4RuCor e Forma:SolidPeso molecular:574.47Ranibizumab
CAS:Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121,Pureza:98%Cor e Forma:LiquidPeso molecular:149.19KDAcrizanib
CAS:Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.Fórmula:C20H18F3N7O2Pureza:98.71% - 99.64%Cor e Forma:SolidPeso molecular:445.4Ref: TM-T5373
1mg111,00€5mg274,00€10mg424,00€25mg723,00€50mg1.008,00€100mg1.311,00€1mL*10mM (DMSO)303,00€VEGFR-2-IN-29
CAS:VEGFR-2-IN-29 is a VEGFR2 inhibitor.Fórmula:C16H11N3O3Pureza:99.59%Cor e Forma:SolidPeso molecular:293.28VEGFR2-IN-4
VEGFR2-IN-4 (compound 25) is a potent, selective inhibitor of the VEGFR2 kinase, exhibiting a GI50 of 0.7 nM and demonstrating anti-angiogenic effects.Fórmula:C23H20N4O3SPureza:98%Cor e Forma:SolidPeso molecular:432.49Anti-VEGFR2/KDR Antibody-APC (4B612)
Anti-VEGFR2/KDR Antibody-APC (4B612) is a APC-conjugated Rabbit antibody targeting VEGFR2/KDR. Anti-VEGFR2/KDR Antibody-APC (4B612) can be used in FCM.Cor e Forma:Odour LiquidAnti-VEGFR2/KDR Antibody-PE (1T318)
Anti-VEGFR2/KDR Antibody-PE (1T318) is a PE-conjugated Mouse antibody targeting VEGFR2/KDR. Anti-VEGFR2/KDR Antibody-PE (1T318) can be used in FCM.Cor e Forma:Odour LiquidAnti-VEGFR2/KDR Antibody-PE (8D594)
Anti-VEGFR2/KDR Antibody-PE (8D594) is a PE-conjugated Rabbit antibody targeting VEGFR2/KDR. Anti-VEGFR2/KDR Antibody-PE (8D594) can be used in FCM.Cor e Forma:Odour LiquidBrivanib
CAS:Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold againstFórmula:C19H19FN4O3Pureza:98.87%Cor e Forma:SolidPeso molecular:370.38Ref: TM-T6036
1mg44,00€5mg94,00€10mg137,00€25mg245,00€50mg355,00€100mg530,00€200mg772,00€1mL*10mM (DMSO)92,00€
